#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Lymphoma Vulval cancer Immune thrombocytopenia Astrocytoma Acute myeloid leukaemia recurrent Congenital cystic kidney disease Progressive familial intrahepatic cholestasis Iron overload Emphysema Fusarium infection Endometrial adenocarcinoma Glomerulonephritis minimal lesion Richter's syndrome Gestational trophoblastic tumour Growth hormone deficiency More trials…

    Learn about Rare Diseases

    KBG syndrome – Treatment CADASIL – Diagnostics Osteosarcoma – Trials in Disease Short-bowel syndrome – Diagnostics Gaucher’s disease type III – Treatment X-linked lymphoproliferative syndrome – Trials in Disease Rhabdoid tumour – Trials in Disease Glomerulonephritis rapidly progressive – Life with Disease Factor VIII deficiency – Basic Information Alexander disease – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    PEGVISOMANT L-PHENYLALANINE Ociperlimab Raltegravir Febuxostat Hemihydrate KETOROLAC TROMETAMOL Oleclumab D5-Ethyl-Beta-D-Glucuronide LYSERGIDE HEMOPEXIN, HUMAN Azd8205 The-630 Rituximab Bi 764524 Quercus Ilex Allergen Extract Edg-5506 Foscarnet Sodium Hexahydrate Alnus Glutinosa Pollen Oxygen Carfilzomib More therapies…

    Learn about Your Condition

    Malignant melanoma of eyelid HER2 positive breast cancer Leiomyosarcoma Glanzmann's disease Cholangiocarcinoma Leukocyte adhesion deficiency Small intestine leiomyosarcoma Mitral valve incompetence Acute myocardial infarction Renal cancer Pulmonary alveolar haemorrhage Deafness neurosensory Bladder cancer stage III Adenocarcinoma gastric Oesophagectomy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hopitaux Universitaires Pitie Salpetriere

Hopitaux Universitaires Pitie Salpetriere

47 Boulevard De L Hopital, Paris, 75651, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effects of Dexmedetomidine on Neuroinflammation in COVID-19 ARDS Survivors

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute respiratory distress syndrome
    Investigated Drugs:
    • Dexmedetomidine
    • N,N-Diethyl-2-(2-(4-(2[(18)F]-Fluoroethoxy)Phenyl)5,7Dimethylpyrazolo[1,5A]Pyrimidin-3-Yl)Acetamide
    France

  • Study to Evaluate Plozasiran for Adults with High Triglycerides

    Not recruiting

    3 1
    Investigated Drugs:
    • Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
    Bulgaria Czechia France Germany Hungary Italy +3

  • Study on the Effectiveness of Human Normal Immunoglobulin for Treating Painful Nerve Damage in Patients with Primary Sjögren’s Syndrome

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Sjogren’s syndrome
    Investigated Drugs:
    • Sodium Chloride Solution 0.9%
    • Human Normal Immunoglobulin
    France

  • Study on Atezolizumab for Patients with Locally Advanced Cervical Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Cervix carcinoma
    Investigated Drugs:
    • Atezolizumab
    France

  • Study of Atezolizumab with BCG Treatment for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Previously Received BCG

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Atezolizumab
    Belgium France Spain

  • Study on Oxaliplatin and Irinotecan for Patients with Metastatic Colorectal Cancer in the Liver

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastases to liver
    • Colorectal cancer
    Investigated Drugs:
    • Oxaliplatin
    Belgium France

  • Study on DF1001, Nivolumab, and Paclitaxel for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Df1001
    • Nivolumab
    • Paclitaxel Albumin-Bound
    Belgium Denmark France The Netherlands

  • Study on the Effectiveness of FOLFOX and Panitumumab for Patients with Metastatic Colorectal Cancer Without RAS Mutation

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal adenocarcinoma
    Investigated Drugs:
    • Panitumumab
    • Folinic Acid
    • Capecitabine
    Belgium France

  • Study of BDC-1001 and Nivolumab for Patients with Advanced HER2-Positive Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Malignant mast cell neoplasm
    • HER2 protein overexpression
    Investigated Drugs:
    • Bdc-1001
    • Nivolumab
    France

  • Study of Atezolizumab with High Dose Radiation vs. Radiation Alone for Patients with Oligometastatic Soft Tissue Sarcoma

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Atezolizumab
    France
Previous Page
1 … 12 13 14 15 16 … 20
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!